Divi’s Laboratories analysts remain divided on prospects after Q4 results; Check key triggers & risks

Kotak Institutional Equities, who is bearish on Divi’s Laboratories, said that the stock’s current valuations of 49 times its estimated price-to-earnings ratio for FY28, is already pricing in growth potential.

Leave a Reply

Your email address will not be published. Required fields are marked *